Scinai’s Intralesional Anti-IL-17 NanoAb Shows Early Promise in Mild to Moderate PsO
Scinai’s intralesional anti-interleukin (IL)-17A/F VHH antibody fragment (‘NanoAb’) is showing promise in an in-vivo preclinical study of mild to moderate psoriasis. Scinai’s product is a biologic intended to be delivered locally, intradermally, into the psoriatic lesions using a very short and almost painless needle. It will allow patients with mild to moderate psoriasis to benefit […]